|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
The MUSASHI (MSI) family of RNA binding proteins (MSI1 and MSI2) contribute to a wide spectrum of cancers including acute myeloid leukemia.
|
31217428 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Translocations and deregulation of the <i>MSI2</i> gene are diagnostic of certain cancers, including chronic myeloid leukemia (CML) with translocation t(7;17), acute myeloid leukemia (AML) with translocation t(10;17), and some cases of B-precursor acute lymphoblastic leukemia (pB-ALL).
|
30126842 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Genetic loss of MSI2 leads to down-regulation of the FLT3 receptor in both AML and BC-CML cells and concomitant impairment of clonogenic growth potential.
|
28107692 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
The Musashi-2 gene (MSI2) is implicated in leukemogenesis, and high MSI2 expression has been associated with decreased survival in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), suggesting its use as a new prognostic marker.
|
25090928 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
In this study, we used lentivirus-mediated RNA interference targeting Msi2 to investigate the resulting changes in cellular processes and the underlying mechanisms in AML cell lines as well as primary AML cells isolated from AML patients.
|
26308531 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
Here, we show that Tetraspanin 3 is a target of the RNA binding protein Musashi 2, which plays a key role in AML.
|
26212080 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
Msi2 has also been found to be overexpressed in human myeloid leukaemias correlating with poor prognosis, therefore Msi2 may be considered as a prognostic marker for acute myeloid leukaemia.
|
22517588 |
2012 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
NUMB expression was significantly lower than that of MSI2 in both MDS and AML patient samples, but no differences in the expression levels for either gene were observed in healthy bone marrow cells.
|
22784712 |
2012 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Expression levels in human myeloid leukemia directly correlate with decreased survival in patients with the disease, thereby defining MSI2 expression as a new prognostic marker and as a new target for therapy in acute myeloid leukemia (AML).
|
20616797 |
2010 |